Description of Medical ServiceThe Pharmacy Diabetes Screening Trial compared three different pharmacy-based screening models:
1. Risk assessment using a validated tool (AUSDRISK) alone (group A)
2. AUSDRISK followed by point-of-care glycated haemoglobin (group B)
3. AUSDRISK followed by point-of-care blood glucose testing (group C)
Description of Medical ConditionDiabetes mellitus is a chronic disorder that reduces the body’s ability to produce and/or use insulin (a hormone produced by the pancreas to regulate blood sugar levels). This results in high blood sugar levels, which lead to serious complications such as stroke; diabetes-related eye disease such as diabetic retinopathy; heart disease; high blood pressure; kidney disease; vascular disease; nerve damage; and foot problems.
Reason for ApplicationThe Sixth Community Pharmacy Agreement provided funding to support a Pharmacy Trial Program (PTP), which seeks to improve clinical outcomes for patients and/or utilise the full scope of a pharmacists role in delivering primary health care services.
The outcomes of all PTP Trials will undergo an independent Health Technology Assessment (HTA) to determine the effectiveness and cost-effectiveness of the trial intervention and inform decisions about any broader rollout. A decision to fund any future programs would be a matter for Government.
Information on the PTP is available on the Department of Health’s website.
Medical Service TypeInvestigative
Previous Application Number/sNot Applicable
Executive SummaryExecutive Summary (PDF 1061 KB)
Executive Summary (Word 57 KB)
Consultation SurveyConsultation Survey (PDF 561 KB)
Consultation Survey (Word 70 KB)
MSAC welcomes public consultation input on the PDST trial as per the Executive Summary document above.
Please complete the Consultation Survey and email your input to commentsMSAC@health.gov.au (and cc: email@example.com) including the MSAC application number 1677 in the subject heading of your email. Consultation closes on 8 October 2021.